Literature DB >> 26921078

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Helen L Reeves1, Marco Y W Zaki2, Christopher P Day3.   

Abstract

Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide. Rather than falling as a result of prevention and treatments for viral hepatitis, an increase is evident in developed nations consequent to the rising prevalence of obesity and type 2 diabetes mellitus (T2DM)-the two major risk factors for nonalcoholic fatty liver disease (NAFLD). The majority of patients with HCC complicating these conditions present with advanced disease as the tools for surveillance are inadequate, and the "at-risk" population is not well characterized. This review will summarize the epidemiological evidence linking obesity, T2DM, and NAFLD with HCC, what is known about the pathogenic mechanisms involved, as well as their relevance for clinicians managing patients at risk. There will also be an overview of the "unmet needs" surrounding this topic, with suggestions for the direction translational research should take in order to prevent progression of NAFLD to HCC, to improve early detection of HCC in those with NAFLD, as well as to improve outcomes for those affected.

Entities:  

Keywords:  Autophagy; Hepatocellular carcinoma; Inflammation; Macrophage; Nonalcoholic fatty liver disease; Obesity; PNPLA3; Type 2 diabetes

Mesh:

Year:  2016        PMID: 26921078     DOI: 10.1007/s10620-016-4085-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  113 in total

1.  Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

Authors:  Marcela Salomao; Woojin M Yu; Robert S Brown; Jean C Emond; Jay H Lefkowitch
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

2.  Focus.

Authors:  Scott L Friedman
Journal:  J Hepatol       Date:  2013-10-08       Impact factor: 25.083

3.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

4.  Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Authors:  Cynthia D Guy; Ayako Suzuki; Marzena Zdanowicz; Manal F Abdelmalek; James Burchette; Aynur Unalp; Anna Mae Diehl
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

5.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

Review 6.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies.

Authors:  Konstantinos K Tsilidis; John C Kasimis; David S Lopez; Evangelia E Ntzani; John P A Ioannidis
Journal:  BMJ       Date:  2015-01-02

Review 7.  A fresh look at NASH pathogenesis. Part 1: the metabolic movers.

Authors:  Claire Z Larter; Shiv Chitturi; Déborah Heydet; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2010-04       Impact factor: 4.029

8.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 9.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  44 in total

Review 1.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

Review 2.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

3.  Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues.

Authors:  Baojin Xu; Wu Lv; Xiaoyan Li; Lina Zhang; Jie Lin
Journal:  Oncol Lett       Date:  2019-04-03       Impact factor: 2.967

Review 4.  Recent advances in hepatocellular carcinoma therapy.

Authors:  Rinku Dutta; Ram I Mahato
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

5.  Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity.

Authors:  Rai Ajit K Srivastava
Journal:  J Diabetes Metab Disord       Date:  2018-11-29

6.  Projections of primary liver cancer to 2030 in 30 countries worldwide.

Authors:  Patricia C Valery; Mathieu Laversanne; Paul J Clark; Jessica L Petrick; Katherine A McGlynn; Freddie Bray
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

Review 7.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

8.  Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era.

Authors:  Chintan Shah; Lazarus K Mramba; Rohit Bishnoi; Harini Bejjanki; Hardik Satish Chhatrala; Sreenivasa R Chandana
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 9.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

Review 10.  Generic chemoprevention of hepatocellular carcinoma.

Authors:  Sai Krishna Athuluri-Divakar; Yujin Hoshida
Journal:  Ann N Y Acad Sci       Date:  2018-09-17       Impact factor: 6.499

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.